Table_1_Novel microRNAs modulating ecto-5′-nucleotidase expression.xlsx by Theresa Kordaß (3475064)

“…MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression at the post-transcriptional level. …”

Image_3_Direct Current Stimulation Disrupts Endothelial Glycocalyx and Tight Junctions of the Blood-Brain Barrier in vitro.tif by Yifan Xia (11331264)

Validation of NUMB as a target for <i>miR-146a</i>. by Pei-Shi Hung (489732)

Novel Antagonist of the Type 2 Lysophosphatidic Acid Receptor (LPA₂), UCM-14216, Ameliorates Spinal Cord Injury in Mice by Nora Khiar-Fernández (8130210)

“…Toward validating this receptor as a target in SCI, we have developed a new series of LPA₂ antagonists, among which compound <b>54</b> (UCM-14216) stands out as a potent and selective LPA₂ receptor antagonist (<i>E</i>_max = 90%, IC₅₀ = 1.9 μM, <i>K</i>_D = 1.3 nM; inactive at LPA_1,3–6 receptors). …”

Novel Antagonist of the Type 2 Lysophosphatidic Acid Receptor (LPA₂), UCM-14216, Ameliorates Spinal Cord Injury in Mice by Nora Khiar-Fernández (8130210)

“…Toward validating this receptor as a target in SCI, we have developed a new series of LPA₂ antagonists, among which compound <b>54</b> (UCM-14216) stands out as a potent and selective LPA₂ receptor antagonist (<i>E</i>_max = 90%, IC₅₀ = 1.9 μM, <i>K</i>_D = 1.3 nM; inactive at LPA_1,3–6 receptors). …”

Synthesis and Biological Evaluation of Peripheral 5HT_2B Antagonists for Liver Fibrosis by Jihyeon Yoon (8705706)

“…<b>19c</b> markedly reduced fibrotic deposition, with a decrease in fibrosis stage and area in the CCl₄-induced liver fibrosis mouse model. …”

Synthesis and Biological Evaluation of Peripheral 5HT_2B Antagonists for Liver Fibrosis by Jihyeon Yoon (8705706)

“…<b>19c</b> markedly reduced fibrotic deposition, with a decrease in fibrosis stage and area in the CCl₄-induced liver fibrosis mouse model. …”

Degradation of cryogels. by Johanna Roether (6102689)

Fig 1 - by Alejandro Lerer (10702204)

Image_1_The P2X7 Receptor 489C>T Gain of Function Polymorphism Favors HHV-6A Infection and Associates With Female Idiopathic Infertility.tif by Anna Pegoraro (8213589)

“…We show that functional P2X7R increases while its blockade decreases viral load. …”

NADPH oxidation and H₂O₂ production by Bs3 and Bs3_S211A. by Christina Krönauer (11301989)

“…NADPH oxidation was monitored via decrease of absorbance at 340 nm. Yucasin and methimazole (MMI) were dissolved in DMSO and added at a final concentration of 50 μM. …”

Study flow and included patients. by Chung-Yeh Chuang (15285925)

“…In the multivariate analysis, being underweight (adjust OR [aOR], 3.80, compared to normoweight; 95% CI, 1.23–11.7) and lower maximal inspiratory airway pressure (aOR per one cmH₂O decrease, 1.05; 95% CI 1.00–1.09) remained significantly associated with extubation failure.…”

Weaning parameters before planned extubation. by Chung-Yeh Chuang (15285925)

“…In the multivariate analysis, being underweight (adjust OR [aOR], 3.80, compared to normoweight; 95% CI, 1.23–11.7) and lower maximal inspiratory airway pressure (aOR per one cmH₂O decrease, 1.05; 95% CI 1.00–1.09) remained significantly associated with extubation failure.…”

S1 Data - by Chung-Yeh Chuang (15285925)

“…In the multivariate analysis, being underweight (adjust OR [aOR], 3.80, compared to normoweight; 95% CI, 1.23–11.7) and lower maximal inspiratory airway pressure (aOR per one cmH₂O decrease, 1.05; 95% CI 1.00–1.09) remained significantly associated with extubation failure.…”

Baseline characteristics of enrolled patients. by Chung-Yeh Chuang (15285925)

“…In the multivariate analysis, being underweight (adjust OR [aOR], 3.80, compared to normoweight; 95% CI, 1.23–11.7) and lower maximal inspiratory airway pressure (aOR per one cmH₂O decrease, 1.05; 95% CI 1.00–1.09) remained significantly associated with extubation failure.…”

The effect of glibenclamide on channel activity at +20, 0 and -20 mV. by Sajjad Salari (736104)

“…Histogram bars show current amplitudes and P_o of reconstituted channels in absence or presence of glibenclamide. The addition of 50 μM glibenclamide resulted in a decreased current jump amplitude and a reduction in P_o. 100 μM glibenclamide caused a total channel inhibition at +20 and 0 mV (n = 5), but was ineffective at -20 mV. …”

Image_3_DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation.tif by Majd Jawad (12157533)

“…By data mining with publicly accessible cancer genomics databases and a clinical genomic database from a tertiary medical institution, DNMT3A R882 mutations were found to be enriched in AML (53% of all DNMT3A mutations) but decreased in frequency in clonal hematopoiesis of indeterminate potential (CHIP) (10.6%) or other myeloid neoplasms including MDS (27%) (p<.001). …”

Image_1_DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation.tif by Majd Jawad (12157533)

“…By data mining with publicly accessible cancer genomics databases and a clinical genomic database from a tertiary medical institution, DNMT3A R882 mutations were found to be enriched in AML (53% of all DNMT3A mutations) but decreased in frequency in clonal hematopoiesis of indeterminate potential (CHIP) (10.6%) or other myeloid neoplasms including MDS (27%) (p<.001). …”

Crystal Structure of YbCu₆In₆ and Mixed Valence Behavior of Yb in YbCu_6–<i>x</i>In_6+<i>x</i> (<i>x</i> = 0, 1, and 2) Solid Solution by Udumula Subbarao (1431364)

“…A deviation in inverse susceptibility data at 200 K suggests a valence transition from Yb²⁺ to Yb³⁺ as the temperature decreases. …”

Image_2_DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation.tif by Majd Jawad (12157533)

“…By data mining with publicly accessible cancer genomics databases and a clinical genomic database from a tertiary medical institution, DNMT3A R882 mutations were found to be enriched in AML (53% of all DNMT3A mutations) but decreased in frequency in clonal hematopoiesis of indeterminate potential (CHIP) (10.6%) or other myeloid neoplasms including MDS (27%) (p<.001). …”